Harrison Global Holdings (NASDAQ: BLMZ) Strikes Game-Changing Biotech Deal with Biotree Co., Ltd.

Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.

Why This Matters to Investors

• Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
• The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
• Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
• Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.

Strategic Synergy

This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.

Executive Insight

"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."

Enrique Vargas

[email protected]

 More On Putoutnews ::

•   Active Baby names the top travel strollers that just fit in the Airplane overhead bin
•   How China Tire Tread Scanner Industry Leader NTA Redefines Maintenance Standards at AMR
•   China Leading Handheld Rail Grinding Wheel Manufacturer: Perfect Match for Grinder Aperture, Flange, Pressure, and Power
•   A Buyer's Guide to Choosing a Professional Smart Monitor Supplier in China: Quality Standards from PERFECT DISPLAY
•   AGII Introduces Development Plan for Behavioral Consensus Logic in Smart Contract Governance

(845) 288-0020